


CLAIMS:

1. A compound of formula (I),



(I)

5

or a pharmaceutically acceptable salt or solvate thereof, wherein

R¹ represents C₁-C₆ alkyl, -(CH₂)_c-[C₃-C₈ cycloalkyl]-, -(CH₂)_c-W or -(CH₂)_c-Z-(CH₂)_d-W;

10

W represents C₁-C₆ alkyl, C₁-C₆ alkyloxy, -CO₂[C₁-C₆ alkyl], -CONR⁴R⁵, a phenyl group, NR⁴R⁵, het² or het³, the phenyl group being optionally substituted with one or more groups independently selected from halogen, CF₃, OCF₃, R³, OR³, CO₂R³, CONR⁴R⁵, CN, SO₂NR⁴R⁵ and NR³SO₂Me;

15

Z represents O or S(O)_g;

g represents 0, 1 or 2;

20

R² represents a phenyl group, optionally fused to a 5- or 6- membered aryl or heterocyclic group which may contain one or more heteroatoms selected from N, O or S; the phenyl group and the optionally fused group being optionally substituted with one or more groups independently selected from the list defined below;

25

Ring A represents a 4-, 5- or 6- membered saturated heterocyclic group containing at least one N;

Ring B represents a phenyl group or het¹, each group being optionally substituted with one or more groups independently selected from the list defined below;

R^7 independently represents H, C₁-C₆ alkyl, OR³, -(CH₂)_e-R³ or -(CH₂)_f-O-(CH₂)_e-R³;

at each occurrence R³ independently represents H, C₁-C₆ alkyl optionally substituted by Y,
5 -(CH₂)_g-[C₃-C₈ cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl;

at each occurrence R⁴ and R⁵ independently represent H, C₁-C₆ alkyl (optionally substituted with C₁-C₆ alkyloxy), (CH₂)₉CO₂-[C₁-C₆ alkyl], -SO₂Me, -(CH₂)₉-[C₃-C₈ cycloalkyl], SO₂Me, phenyl, benzyl, pyridyl or pyrimidyl; or R⁴ and R⁵ together with the N
10 atom to which they are attached represent a heterocyclic group of from 3 to 8 atoms;

Y independently represents a phenyl group, NR⁴R⁵ or het⁴, the phenyl group being optionally substituted with one or more groups independently selected from halogen, CF₃, OCF₃, R⁴, OR⁴, CO₂R⁴, CONR⁴R⁵, CN, SO₂NR⁴R⁵, NR⁴SO₂Me and -NR⁴R⁵;

15

het¹ represents a 4-, 5- or 6- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may also contain one or more O or S atoms);

het² represents a 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group
20 containing at least one N (but which may also contain one or more O or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

het³ represents a 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group
25 containing at least one O (but which may also contain one or more N or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

het⁴ represents a 4-, 5-, 6- or 7- membered saturated or unsaturated heterocyclic group
30 containing at least one N (but which may also contain one or more O or S atoms), optionally substituted with one or more groups independently selected from the list defined below;

substituents for R², Ring **B**, het¹, het², het³ and het⁴ are independently selected from the
35 following list: halogen, CF₃, OCF₃, R³, -(CH₂)_e-SO₂Me, -(CH₂)_e-OR³, -(CH₂)_e-CO₂R³, -

$(\text{CH}_2)_e\text{-CONR}^4\text{R}^5$, $-(\text{CH}_2)_e\text{-CN}$, $-(\text{CH}_2)_e\text{-SO}_2\text{NR}^4\text{R}^5$, $-(\text{CH}_2)_e\text{-NR}^3\text{SO}_2\text{Me}$, $-(\text{CH}_2)_e\text{-COR}^3$, $-(\text{CH}_2)_e\text{-OCOR}^3$, $-(\text{CH}_2)_e\text{-NHCOR}^3$, $-(\text{CH}_2)_e\text{-NR}^3\text{COR}^6$ and $-(\text{CH}_2)_e\text{NR}^4\text{R}^5$;
 at each occurrence R^6 independently represents H, $\text{C}_1\text{-C}_6$ alkyl optionally substituted by Y,
 $-(\text{CH}_2)_g\text{-[C}_3\text{-C}_8\text{ cycloalkyl]}$, phenyl, benzyl, pyridyl or pyrimidyl;

5

a and b independently represent 0 or 1;

c, d, e and g independently represent 0, 1, 2, 3 or 4;

10 f independently represents 1, 2, 3 or 4;

provided that:

(i) a + b cannot equal 0; and

15

(ii) provided that when R^1 represents $-(\text{CH}_2)_c\text{-Z-(CH}_2)_d\text{-W}$ and W represents NR^4R^5 or any N linked heterocyclic group then d must not be 0 or 1; and

20

(iii) provided that when R^2 represents a phenyl group substituted by a group of formula $-(\text{CH}_2)_e\text{OR}^3$, $-(\text{CH}_2)_e\text{-CO}_2\text{R}^3$ or $-(\text{CH}_2)_e\text{OCOR}^3$; or het^1 and/or het^2 are substituted by a group of formula $-(\text{CH}_2)_e\text{OR}^3$, $-(\text{CH}_2)_e\text{-CO}_2\text{R}^3$ or $-(\text{CH}_2)_e\text{OCOR}^3$; or when R^7 represents $-\text{OR}^3$ or $-(\text{CH}_2)_f\text{-O-(CH}_2)_e\text{-R}^3$ and e is 0; or when W represents a phenyl group substituted with $-\text{OR}^3$ or $-\text{CO}_2\text{R}^3$; and

25

R^3 represents an alkyl group substituted with Y, and Y represents NR^4R^5 or an N-linked het^3 ;
 then R^3 must represent $\text{C}_2\text{-C}_6$ alkyl substituted with Y.

30 2. A compound according to claim 1, wherein R^2 is a phenyl group optionally substituted with one or more groups selected from halogen or $-(\text{CH}_2)_e\text{-OR}^3$.

3. A compound according to claim 1 or claim 2, wherein ring A is selected from piperidindiyl, piperazindiyl, azetidindiyl or pyrrolidindiyl.

35

4. A compound according to claim 3, wherein ring A is piperidindyl.
5. A compound according to any of the preceding claims, wherein Z is O.
6. A compound according to any of the preceding claims, wherein het¹ is selected from
5 optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, piperidinyl, piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl or pyrrolidinyl.
7. A compound according to any claim 6, wherein het¹ is selected from pyridinyl or
10 pyrimidinyl, optionally by R³.
8. A compound according to any of the preceding claims, wherein het² is selected from substituted or unsubstituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, piperidinyl,
15 piperazinyl, N-methyl piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl or pyrrolidinyl.
9. A compound according to claim 8, wherein het² is selected from imidazolyl, piperidinyl, piperazinyl, N-methyl piperazinyl, azetidiny, morpholinyl, 2-oxa-5-aza-
20 bicyclo[2.2.1]heptanyl or pyrrolidinyl.
10. A compound according to any of the preceding claims, wherein a is 1 and b is 0.
11. A compound according to claim 1, which is selected from
25 (S)-4-[5-Butyl-4-(1-phenyl-ethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
2-[4-(4-Benzyl-5-isobutyl-4H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
(S)-4-[5-Methyl-4-(1-phenyl-ethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
30 4-[4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl;
2-[4-(4-Benzyl-5-isopropyl-4H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
2-[4-(4-Benzyl-5-cyclopropyl-4H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
(S)-2-[4-[5-Methyl-4-(1-phenyl-propyl)-4H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-
pyrimidine;
35 2-[4-(4-Benzyl-5-propyl-4H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;

- 2-{4-[4-Benzyl-5-(2-chloro-phenoxy-methyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- 2-[4-(4-Benzyl-5-butyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
- (*S*)-2-{4-[5-Methyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- 5 2-[4-[4-Benzyl-5-(4-fluoro-phenoxy-methyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl]-pyrimidine;
- 2-{4-[5-Methyl-4-(3-methyl-benzyl)-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl}-pyrimidine;
- (*S*)-2-{4-[5-Methyl-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-ylmethyl]-piperidin-1-yl}-pyrimidine;
- 10 2-[4-[4-(3-Fluoro-benzyl)-5-methyl-4*H*-[1,2,4]triazol-3-yl]-piperidin-1-yl]-pyrimidine;
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 4-(4-Benzyl-5-benzyloxymethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 15 4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*R*)-2-[3-Methyl-5-(1-pyrimidin-2-yl-piperidin-4-yl)-[1,2,4]triazol-4-yl]-2-phenyl-ethanol;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-4-methyl-pyrimidine;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrimidine;
- 20 4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-1-phenyl-piperidine;
- 2-[4-(4-Benzyl-5-methyl-4*H*-[1,2,4]triazol-3-yl)-piperidin-1-yl]-pyrazine;
- 4-(4-Benzyl-5-piperidin-1-ylmethyl-4*H*-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*S*)-4-[4-(1-Phenyl-ethyl)-5-piperidin-1-ylmethyl-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-
- 25 tetrahydro-2*H*-[1,2']bipyridinyl;
- 4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- (*S*)-4-[5-(4-Methoxy-piperidin-1-ylmethyl)-4-(1-phenyl-ethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl;
- 30 4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl-4-yl)-4*H*-[1,2,4]triazol-3-ylmethyl]-piperazine-1-carboxylic acid benzyl ester;
- 4-[4-Benzyl-5-(2-morpholin-4-yl-ethoxymethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2*H*-[1,2']bipyridinyl.
- 4-[4-Benzyl-5-((3*R*)-3-methoxy-pyrrolidin-1-ylmethyl)-4*H*-[1,2,4]triazol-3-yl]-3,4,5,6-
- 35 tetrahydro-2*H*-[1,2']bipyridinyl

- 4-[4-Benzyl-5-((3S)-3-methoxy-pyrrolidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 1-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-pyrrolidin-3-ol
- 5 4-(4-Benzyl-5-pyrrolidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 10 4-[4-(4-Fluoro-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-(3-Methoxy-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 15 4-[5-Methyl-4-(3-methyl-benzyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-(3-Chloro-benzyl)-5-methyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]-acetamide
- 20 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-ethylamine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-ethyl-amine
- 25 [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(2-methoxy-ethyl)-amine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(3-methoxy-propyl)-amine
- 1-{4-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-piperazin-1-yl}-ethanone
- 30 4-[4-Benzyl-5-(4-methanesulfonyl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl
- N-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-methanesulfonamide

- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(2-methoxy-ethyl)-methyl-amine
- [4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-(3-methoxy-propyl)-methyl-amine
- 5 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carbonitrile
- 10 4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid amide
- (S)-4-[4-(1-Phenyl-ethyl)-5-(4-pyridin-2-yl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-ylmethyl]-morpholine trihydrochloride
- 15 (S)-4-[4-(1-Phenyl-ethyl)-5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-4H-[1,2,4]triazol-3-ylmethyl]-morpholine trihydrochloride
- 1-[4-Benzyl-5-(1-pyrimidin-2-yl-piperidin-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-piperidin-3-ol
- (R)- 2-[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester
- 20 (R)-4-[4-Benzyl-5-(tetrahydro-furan-3-yloxymethyl)-4H-[1,2,4]triazol-3-yl] 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- (S)-4-[4-Benzyl-5-(tetrahydro-furan-3-yloxymethyl)-4H-[1,2,4]triazol-3-yl] 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 25 {[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethyl]-methyl-amino}-acetic acid tert-butyl ester
- 4-[4-Benzyl-5-(tetrahydro-pyran-4-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(tetrahydro-furan-2-yl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 30 4-(4-Benzyl-5-ethoxymethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
- 4-[4-Benzyl-5-(2-methoxy-ethoxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

[4-Benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-acetic acid tert-butyl ester

N-Benzyl-2-[4-benzyl-5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H-[1,2,4]triazol-3-ylmethoxy]-acetamide

5 4-(4-Benzyl-5-methylsulfanylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-pyrazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

10 4-(4-Benzyl-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-[1,2,3]triazol-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-[4-Benzyl-5-(pyridin-4-yloxymethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl.

15

12. A compound according to claim 11, which is selected from:

4-[4-Benzyl-5-butyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-morpholin-4-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

20 4-(4-Benzyl-5-benzyloxymethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-(4-Benzyl-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl


25 (S)-4-[4-(1-Phenyl-ethyl)-5-piperidin-1-ylmethyl-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

4-[4-Benzyl-5-(4-methoxy-piperidin-1-ylmethyl)-4H-[1,2,4]triazol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl

30 13. The use of a compound according to formula (I) as a medicament.

14. A method of treatment of aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhoea, edema, 35 emesis, endometriosis, gastrointestinal disease, glaucoma, gynaecological disease, heart

- disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittelschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection, urolithiasis, comprising administering a therapeutically effective amount of a compound of formula (I) to a patient suffering from such a disorder.
- 10 15. A method according to claim 14 wherein the disorder is dysmenorrhoea.
- 15 16. The use of a compound of formula (I) in the manufacture of a medicament for the treatment of aggression, Alzheimer's disease, anorexia nervosa, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, cerebrovascular ischemia, cirrhosis, cognitive disorder, Cushing's disease, depression, diabetes mellitus, dysmenorrhoea, edema, emesis, endometriosis, gastrointestinal disease, glaucoma, gynaecological disease, heart disease, hypertension, hyponatremia, intrauterine growth retardation, ischemia, ischemic heart disease, lung tumor, micturition disorder, mittelschmerz, motion sickness, neoplasm, nephrotoxicity, non-insulin dependent diabetes, obesity, obsessive/compulsive disorder, ocular hypertension, premature ejaculation, premature labor, pulmonary disease, Raynaud's disease, renal disease, renal failure, male and female sexual dysfunction, sleep disorder, spinal cord injury, thrombosis, urogenital tract infection, urolithiasis.
- 20 25 17. Use according to claim 16 for the treatment of dysmenorrhoea.
18. A pharmaceutical formulation including a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable excipients, diluent or carrier;
- 30 19. An intermediate of formula (II):



wherein R^1 , rings A and B, and b are as defined in claim 1.

20. Use of a V1a antagonist in combination with an oral contraceptive for the treatment
5 of dysmenorrhoea.

21. Use according to claim 20 wherein the V1a antagonist comprises a compound
according to any of claims 1 to 12.